Skip To Main Content
Barry Heller on Muck Rack

Barry Heller

As seen in: The New England Journal of Medicine, JD Supra, American Society for Microbiology (ASM)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barry

Contact Barry, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

|
By Peter Chen, Barry Heller, Robert Gottlieb, Joseph Boscia
| The New England Journal of Medicine Verified
24 References 190 Citing Articles Letters Related Articles Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, and prevent hospitalization.
Open in Who Shared Issue with article?

Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid

|
By Frederick Wittke, Catherine Vincent, James Chen, Barry Heller
| American Society for Microbiology (ASM)
Clinical Therapeutics Frederick Wittke, Catherine Vincent, James Chen, Barry Heller, Heidi Kabler, J. Scott Overcash, François Leylavergne, Guennaëlle Dieppois DOI: 10.1128/AAC.00250-20 ABSTRACT Afabicin (formerly Debio 1450, AFN-1720) is a prodrug of afabicin desphosphono, an enoyl-acyl carrier protein reductase (FabI) inhibitor, and is a first-in-class antibiotic with a novel mode of action to specifically target fatty acid synthesis in Staphylococcus spp.
Open in Who Shared Issue with article?

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

|
By Peter Chen, Barry Heller, Robert Gottlieb, Joseph Boscia
| The New England Journal of Medicine Verified
24 References 37 Citing Articles Letters Related Articles Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, and prevent hospitalization.
Open in Who Shared Issue with article?
See all 4 articles